The little mouse is a dwarf strain characterized by low levels of GH, pituitary hypoplasia, and an unresponsiveness to treatment with exogenous GHRH. The defect has been mapped to a missense mutation in the GHRH receptor gene that abolishes the function of the receptor, but the mechanism of this inactivation is unknown. Receptor function might be affected at the level of protein expression, maturation and processing, localization to the cell surface, ligand binding, or signaling. In this study, Western blots, using antiserum raised against the GHRH receptor and immunoprecipitation analysis of epitope-tagged receptors, demonstrate that both wild-type and mutant receptor proteins are expressed at equivalent levels in transfected cells. Immunofluorescence analysis of intact and permeabilized cells expressing the epitope-tagged receptors suggests that wild-type and little mouse receptors are similarly localized to the cell surface. A species homologous binding assay was developed and used to show that 125 I-mouse GHRH binds with high affinity to the wild-type mouse receptor but not to the little mutant receptor. Consistent with this, the mutant receptor fails to stimulate intracellular cAMP accumulation. Our results demonstrate that the little mutation does not dramatically affect the expression level, glycosylation, or cellular localization of the receptor protein but that it blocks specific GHRH binding, and therefore, signaling does not take place. (Endocrinology 140: 5066 -5074, 1999) G ROWTH IN VERTEBRATES is controlled by the hypophyseotropic peptides somatostatin and GHRH, which suppress and stimulate, respectively, the secretion of GH from the somatotroph cells of the anterior pituitary (1, 2). GHRH is a peptide hormone produced by the neurosecretory cells of the hypothalamic arcuate nuclei that acts through its receptor on pituitary somatotroph cells, resulting in G protein coupling, adenylyl cyclase activation and cAMP production, Ca 2ϩ influx, and increased expression and secretion of GH.
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The little mouse is a dwarf strain with an autosomal recessive defect characterized by substantially reduced levels of circulating GH and GH messenger RNA (mRNA) and anterior pituitary hypoplasia, with fewer pituitary somatotroph cells and sparse granulation (3) (4) (5) (6) (7) . Cultured somatotroph cells from these animals do not release GH upon GHRH treatment but secrete GH upon treatment with cAMP or agents that increase cAMP levels, indicating that the defect is in the GHRH signaling pathway (5, 6) . Genetic mapping and cloning studies have localized this defect to a point mutation in the N-terminal extracellular domain of the GHRH receptor (8, 9) , where an aspartic acid residue at position 60 is mutated to glycine. Consistent with the dwarf phenotype, the mutant receptor is inactive, and cells expressing the mutant receptor do not accumulate cAMP in response to GHRH (8, 9) . Mutations in the GHRH receptor have recently been identified in heritable isolated GH deficiencies in humans (10 -13) , and thus, establishment of the molecular and cellular basis of these inactivating mutations promises to enhance our understanding not only of normal regulation of the GH axis but also of diseases of GH secretion.
The GHRH receptor belongs to family B-III of the G protein-coupled receptor (GPCR) superfamily (14) , whose members include the receptors for secretin, vasoactive intestinal peptide (VIP), pituitary adenylate cyclase-activating peptide (PACAP), GLP-1, glucagon, and glucose-dependent insulinotropic polypeptide (GIP, also known as gastric inhibitory peptide). All these receptors share a high degree of homology and share several conserved residues, including the aspartic acid residue that is mutated in the little mouse. In all receptors of family B-III, the N-terminus has been shown to be important for ligand binding (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) . Studies on the GHRH receptor have indicated that the N-terminus is essential for ligand binding (24 -26) but that the N-terminus from VIP or secretin receptors can substitute for the GHRH receptor Nterminus, resulting in chimeric receptors that bind GHRH (24) . This demonstrates that residues of the transmembrane domains and/or the connecting extracellular loops are important in determining the specificity of ligand binding.
There are multiple levels at which the mutation of the aspartate 60 to glycine in the GHRH receptor might impact receptor function. It could influence the folding of the receptor protein, resulting in protein instability and thus decreased levels of receptor expression. It could affect transport of the receptor through the endoplasmic reticulum-Golgi network, resulting in lower cell surface expression of the receptor protein. The mutation could also alter receptor glycosylation, because it is only 10 residues from the single site for N-linked glycosylation at amino acid 50. Alternatively, the GHRH receptor protein might be normally expressed, but the little mutation might impact the ability of the receptor to bind its ligand, GHRH. Finally, the mutation might interfere with an appropriate hormone-induced conformational change affecting G protein coupling and signaling. To characterize the defect in the GHRH receptor of the little mouse, we used protein blot analysis and immunoprecipitation to compare expression and glycosylation of the wildtype and mutant receptor proteins and immunofluorescence analysis to compare the subcellular localization of the 2 receptors. We also developed a homologous binding assay for the mouse GHRH receptor and compared the ability of the wild-type and mutant GHRH receptors to bind GHRH and to activate adenylyl cyclase. Our results point to a selective defect in GHRH binding by the little mutant GHRH receptor.
Materials and Methods

Generation of stable cell lines
Full-length complementary DNA (cDNA) clones for the mouse GHRH receptors were isolated by RT-PCR amplification of pituitary RNA from homozygous wild-type and little mice, as described (8) . The cDNAs were subcloned into the eukaryotic expression vector pcDNA-1 and used for the generation of stable cell lines. HEK293 cells were transfected using lipofectin reagent (Life Technologies, Inc., Gaithersburg, MD) and 10 g DNA/100 mm plate at a 9:1 ratio of the cDNA expression construct to pSV2neo. Transfected cells were selected in the presence of 400 g/ml G418 (Sigma, St. Louis, MO), and individual clones were isolated and expanded for analysis. Cells were tested for expression of the receptor mRNAs by Northern analysis, and clones expressing comparable levels of mRNA for the two receptors were maintained in 400 g/ml G418 and used for Western analysis and binding and signaling studies. The cells stably expressing the human GHRH receptor were generated previously (27) .
Generation of antibodies to the GHRH receptor and Western blotting
The synthetic peptide Ac-HMHPEADFITQLREDESAALQAAC-COOH, modeled after the proposed N-terminus of the mature human GHRH receptor after signal peptide cleavage (28) and with two internal cysteines replaced with alanines, was prepared by solid-phase synthesis and purified by HPLC, and its identity was confirmed by mass spectrometry (University of Virginia Biomolecular Research Facility). This peptide was then coupled through a C-terminal cysteine to maleimideactivated keyhole limpet hemocyanin (Pierce Chemical Co., Rockford, IL) and used to raise antiserum in rabbits (HRP Antiserum Services, Denver, PA). This crude antiserum was used directly for the detection of mouse or human GHRH receptor by Western analysis.
Crude membranes from HEK293 cells expressing the various receptors were extracted in 5 mm 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) and 11.4 g of total protein, as measured using the bicinchoninic acid assay (Pierce Chemical Co.), was electrophoresed on SDS-polyacrylamide gels with prestained low-range molecular weight standards (Life Technologies, Inc.), as previously described (29) . Deglycosylation was performed by treatment with peptide-N-glycosidase F (PNGase F) (Roche Molecular Biochemicals, Indianapolis, IN), as described (29) . The separated proteins were then electroblotted to nitrocellulose membrane (Protran, Schleicher & Schuell, Inc., Keene, NH), and electrophoretic transfer to nitrocellulose was confirmed by ponceau S staining of the blot. Crude rabbit sera, before (preimmune) or after immunization, were used at a 1:10,000 dilution and incubated with blots at 4 C overnight. The antibodyantigen complexes were detected by incubation with a 1:10,000 dilution of horseradish peroxidase-conjugated goat antirabbit antibody and visualized using the enhanced chemiluminescence method (Amersham Pharmacia Biotech, Arlington Heights, IL).
Generation and expression of epitope-tagged receptor constructs
An oligonucleotide primer complementary to the 3Ј end of the mouse GHRH receptor and encoding the sequence for the hemagglutinin (HA) epitope (30) was synthesized. Recognition sites for the enzymes KpnI and XbaI were engineered on either side of the HA epitope with the stop codon within the XbaI site. This primer, together with an upstream primer within the third intracellular loop of the receptor cDNA was used to amplify a 700-bp fragment from the 3Ј region of the receptor. The PCR product was cloned in context with the 5Ј end of the wild-type or mutant receptor into the expression vector pcDNA-3 (Invitrogen, San Diego, CA) to generate full-length constructs for the wild-type and mutant receptor, having the HA epitope at the C-terminus [mGHRHRwt.HA (wild-type mouse GHRH receptor) and mGHRHRlit.HA (little mouse GHRH receptor)].
An oligonucleotide primer complementary to the 5Ј end of the mouse GHRH receptor and encoding the sequence for the FLAG epitope (31) was synthesized and used along with a downstream primer in the third transmembrane domain of the receptor, to amplify a 700-bp fragment from the 5Ј end of the cDNAs of the wild-type and little mouse GHRH receptors. The PCR products from the wild-type and little mouse receptor were cloned in context with the 3Ј end of the receptor into the expression vector pcDNA-3, to generate full-length constructs for the respective receptors having the FLAG epitope at the N-terminus (mGHRHRwt.FLAG and mGHRHRlit.FLAG).
To assess the activity of the epitope-tagged wild-type mouse GHRH receptors, ligand binding and signaling were measured, and it was observed that the presence of the HA tag did not affect the activity of the receptor. The introduction of the FLAG tag at the N-terminus of the wild-type mouse GHRH receptor disrupted hormone binding in a manner similar to the FLAG-tagged human GHRH receptor (24); however, the receptor was expressed at levels comparable with the HA-tagged wild-type receptor and was present at the cell surface of intact cells.
The epitope-tagged constructs of the wild-type and mutant mouse GHRH receptors were expressed in HeLa T4 cells, as described (24), using the Vaccinia virus-T7 RNA polymerase system (obtained under license from Dr. Bernard Moss, National Institutes of Health, Bethesda, MD) (32) . Cells were transfected using plasmid DNAs that were complexed with liposomes at a ratio of 4 -5 g lipid/g DNA (33) . (24), using the anti-HA monoclonal antibody 12CA5 (a gift from Dr. R. A. Lamb, Northwestern University). The samples were separated by SDS-PAGE using a Tris-glycine buffer with See-Blue Pre-Stained Standard (Novex, San Diego, CA) as size markers. The gels were fixed in 20% methanol/7% acetic acid, saturated with glacial acetic acid, impregnated with 22% wt/vol of 2,5-diphenyl-oxazole in acetic acid, dried, and exposed to Kodak X-OMAT AR film (Eastman Kodak Co., Rochester, NY).
Metabolic labeling of transfected cells and immunoprecipitation of epitope-tagged receptors
Immunofluorescence localization of the wild-type and mutant epitope-tagged receptors
Subconfluent monolayers of HeLa T4 cells, cultured on glass coverslips, were transfected, the coverslips were washed twice in PBS, and immunofluorescense analysis was performed as described (24) . For permeabilized cells, the coverslips were incubated for 2 h at 4 C with 3 g/ml of the anti-FLAG M2 monoclonal antibody (Kodak IBI Division, New Haven, CT) or 1 g/ml of the HA specific 12CA5 ascites fluid in PBS containing 0.1% saponin. After washing, the coverslips were incubated at 4 C for 30 min with 2 g/ml fluorescein isothiocyanate-conjugated goat antimouse secondary antibody (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) in PBS containing 0.1% saponin and 0.2% whole goat serum, washed with PBS, and mounted using FITCGuard (Testog Inc., Chicago, IL). For nonpermeabilized cells, incubation was carried out using similar conditions with primary and secondary antibodies diluted in PBS (without saponin). The images of cells are optical sections obtained using confocal laser scanning microscopy with a Bio-Rad Laboratories, Inc. MRC 600 connected to a Nikon microscope using a 40ϫ objective. All samples were scanned using the same contrast settings for equivalent times, and optical sections were taken through the central plane of the cell.
Iodination of GHRH analogs and assay of GHRH binding and cAMP accumulation
Mouse GHRH and [His 1 , Nle 27 ]human GHRH (1-32)NH 2 were purchased from Peninsula Laboratories, Inc. (Belmont, CA). These were iodinated to low stoichiometry using the Iodobead method (Pierce Chemical Co.) and purified by reverse-phase HPLC, as previously described (29) .
GHRH binding was measured in crude membrane pellets permeabilized with alamethicin, as described (29) . Each tube contained approximately 100,000 cpm of probe corresponding to approximately 3.5 ϫ 10 Ϫ11 m 125 I-GHRH and was incubated for 1 h at room temperature. The crude membranes were pelleted, detergent extracted with 5 mm CHAPS, and free GHRH was removed with charcoal-dextran. Soluble, receptorbound GHRH was then assayed using a ␥-counter (29) . The binding data were analyzed by nonlinear least-squares fitting to model curves using the computer program Ligand (34) . Intracellular cAMP was assayed by RIA of extracts from cells grown in 24-well cluster plates and pretreated with isobutylmethylxanthine, as described (28) .
Photoaffinity cross-linking
The UV-activatable heterobifunctional cross-linking reagent ANB-NOS (Pierce Chemical Co.) was coupled at low stoichiometry to the lysines of [His 1 , Nle 27 ]human GHRH (1-32)NH 2 , and the crude products were iodinated as above. The iodinated photoprobe was then purified from this mix by HPLC, and used in the GHRH binding protocol, as described above. After 60-min binding, the GHRH-receptor complexes were cross-linked with long-wave UV, SDS denatured, analyzed by gel electrophoresis as described for Western blots, and then autoradiographed as described (29) . Endoglycosidase H was obtained from Roche Molecular Biochemicals (Indianapolis, IN)
Results
Immunological detection of the mouse GHRH receptor
A polyclonal antiserum against the GHRH receptor was raised in rabbits using a synthetic peptide corresponding to the first 23 amino acids of the predicted N-terminus of the human GHRH receptor as the antigen. This region is highly conserved among GHRH receptors from different species, but is not conserved in related receptors that bind other ligands. Because 19 of these 23 amino acids are identical in the human and mouse GHRH receptors, this strategy allowed the production of an antiserum found to recognize human, mouse, and also rat GHRH receptors.
The specificity of the antiserum for the GHRH receptor was confirmed by using it to probe Western blots of CHAPSextracted crude membranes from nontransfected HEK293 cells and from cells transfected with the mouse, little mouse, and human GHRH receptors (Fig. 1) . Consistent with previous GHRH cross-linking studies (29) , a band of approximately 52 kDa was detected in cell lines transfected with the human GHRH receptor cDNA (Fig. 1D, lane 2) . A similar band of slightly greater mobility was seen in cell lines transfected with either wild-type mouse or little mouse GHRH receptors (Fig. 1, B and C) . This band was not observed in control HEK293 cells, and it was not detected by preimmune serum in the control or receptor-expressing cell lines. As a further proof of specificity, inclusion of excess of the synthetic peptide immunogen blocked the labeling of this band by GHRH receptor antibody. After treatment with PNGase F (Fig. 1, lane 3) , the receptor-specific band shifted to a greater apparent mobility, as expected from our previous observations of receptor glycosylation (29) . Because deglycosylation with endoglycosidase H (not shown) gave the same results as the PNGase F treatments in Fig. 1 , this suggests that the glycosylation of both wild-type and little GHRH receptors seen in these Western blots is of the high mannose, core-glycosylated type.
UV cross-linking, using iodinated GHRH photoprobe and electroblotting under the same conditions as the Western blots, shows both complex and core-glycosylated forms of the GHRH receptor in cell lines expressing the wild-type receptor (Fig. 2) . To better resolve receptor glycosylation forms, these gels were run in 10% polyacrylamide vs. 7.5% polyacrylamide in Fig. 1. In Fig. 2 , lane 2 demonstrates three distinct receptor glycosylation forms, each of which bind GHRH, because they are detected by cross-linking of the labeled ligand. Lane 3 shows that all of these forms can be deglycosylated to a higher mobility form by PNGase F. Laneand complex glycosylated forms of the wild-type GHRH receptor are accessible in our permeabilized binding assay and bind GHRH. Thus, complex glycosylation is not required for GHRH binding. It is not clear why the complex glycosylated receptor was not detected by Western analysis.
The experiments with untagged receptors used stable cell lines expressing mouse and little mouse receptors that had been selected from multiple clones for matched levels of receptor mRNA using Northern analysis. For the work with epitope-tagged receptors, we used a transient expression system that allowed us to obtain higher and more consistently matched receptor expression levels. The cDNAs for the wild-type and little mouse GHRH receptors were modified to include the sequence for an HA epitope at the C-terminus of the expressed protein. Immunoprecipitation of the epitope-tagged mouse GHRH receptors transiently transfected in HeLa T4 cells (Fig. 3) , using anti-HA monoclonal antibody 12CA5, confirmed that the wild-type and mutant receptor proteins were produced in similar abundance.
Cellular localization of the wild-type and mutant mouse GHRH receptors
The cDNAs for the wild-type and little mouse GHRH receptors were also modified to insert the sequence for the FLAG epitope at the N-terminus of the expressed receptor so that an extracellular epitope could be used to detect the protein. These constructs were used to determine the cellular localization of the GHRH receptors in intact cells. The previously described human GHRH receptor, having an Nterminal FLAG-tag (hGHRHR.FLAG), was used as a control in these experiments (24) . Indirect immunofluorescence detection of both the FLAG-and HA-tagged mouse GHRH receptors was performed using monoclonal antibodies against the epitope-tags, and the localization of the receptors was recorded using confocal microscopy (Fig. 4) . In intact cells expressing the FLAG-tagged receptors, it was observed that the mutant GHRH receptor was localized on the cell surface in a manner indistinguishable from that of the wildtype receptor, whereas in permeabilized cells expressing either the FLAG-or HA-tagged receptors, the receptors were present both on the cell surface and intracellularly. Again, no differences in the cellular distribution of the wild-type and little receptors were observed. Thus, aspartate 60 is not required for receptor protein expression, core glycosylation, or appropriate transport to the cell surface, although it may be required for attaining a receptor conformation necessary for high-affinity GHRH binding and subsequent activation of G S ␣. To test this possibility, we developed a species homologous ligand-binding assay for the mouse GHRH receptor.
Ligand binding by the mouse GHRH receptor
In initial attempts to use 125 I-human GHRH to analyze ligand interaction with the mouse GHRH receptor from membranes of transfected HEK293 cells, we were unable to detect any specific binding to the wild-type mouse receptor. We therefore iodinated mouse GHRH and used the homologous ligand to establish a GHRH-binding assay for the mouse GHRH receptor. Saturation binding revealed that the binding affinities of the wild-type mouse and human receptors for their homologous ligand were not statistically different, with dissociation constant (K d ) values of 0.162 nm and 0.136 nm respectively (Fig. 5) , with the receptor protein expressed at 210 and 18.9 fmol/mg protein, respectively. Competition binding of both mouse and human GHRH to membranes from cell lines expressing the mouse or human receptor was performed, and the data were normalized to the amount of receptor expressed. As shown in Fig. 6 , each receptor bound better to the species-homologous ligand. Under these assay conditions, the specific binding of human GHRH to the mouse GHRH receptor was less than 10% of that seen with mouse GHRH in the same membrane preparation, explaining our previous inability to detect specific binding of human GHRH to the mouse receptor. 
Binding and signaling by the little mouse GHRH receptor
Mouse GHRH binding to crude membrane preparations was measured for HEK293 cells that were transfected with the wild-type or little mouse GHRH receptors and for nontransfected controls (Fig 7) . Specific binding of GHRH to the wild-type receptor was competed by GHRH and decreased by the G protein uncoupling agent guanosine 5Ј-O-(3-thiotriphosphate) (GTP␥S). Because some types of receptor mutations can cause inactivation resulting from intracellular accumulation of protein (35) , this binding assay employed homogenized and permeabilized cell membranes to detect binding by both cell surface and intracellular membranes. Though binding to wild-type receptor could be detected on intact live cells, more apparent binding sites were seen in permeabilized membrane preparations, consistent with the presence of functional receptor at both surface and internal sites. GHRH binding to the little mouse receptor containing permeabilized membranes was no greater than to membranes from nontransfected cells, indicating that the mutant receptor was unable to bind GHRH.
Intracellular cAMP accumulation in response to mouse GHRH was measured, and it was observed that cells expressing the wild-type receptor accumulated cAMP in a dose-dependent manner. As expected (based on the binding data), cells expressing the little mouse GHRH receptor did not accumulate cAMP at significantly higher levels than the nontransfected controls (Fig. 8) , confirming our previous findings in a different cell background (8) .
Discussion
GHRH and its receptor are key proteins for the proliferation and differentiation of pituitary somatotroph cells, for the stimulation of GH synthesis and secretion, and the regulation of somatic growth (2, 36) . The high-affinity binding of GHRH to its receptor on pituitary somatotroph cells is therefore a critical event for normal functioning of the GH axis. The little mouse mutation has been studied extensively as a model for human isolated GH deficiency type 1B, and recently profound growth failure analogous to that seen in the little mouse has been observed in humans homozygous for mutations in the GHRH receptor gene (10 -13) . Three studies involving distantly related kindreds identified a mutation in the human GHRH receptor gene that introduced a premature stop codon into the mRNA, 12 bp downstream from the site where the little mouse mutation occurs, thus encoding a truncated receptor predicted to be nonfunctional (10 -12) . Data from another study revealed a mutation in a donor splice site that causes the gene's first intron to be retained in the mRNA, resulting in a disruption of the translational reading frame of the protein (13) . It is anticipated that   FIG. 4 . Immunological localization of the epitope-tagged mouse GHRH receptor. The cellular localization of the FLAG-or HA-epitope-tagged wild-type and little mouse GHRH receptors was determined using indirect immunofluorescence. A, Images of intact cells transfected with the indicated constructs and detected using the monoclonal antibody to the FLAG-epitope tag. Two different fields have been shown for cells expressing the wild-type and the little mouse GHRH receptors. B and C, Images of cells expressing the indicated constructs that have been permeabilized with 0.1% saponin and detected using the monoclonal antibody against either the FLAG (B) or HA (C) epitope tags. All images were scanned using a confocal microscope, under the same contrast settings for equivalent times, and they are representative of at least two independent experiments. other GHRH receptor mutations will be discovered in patients with abnormalities of GH secretion, and studies on the little mouse should thus prove useful as a model of human disease.
Several inherited human diseases have been attributed to single amino acid substitutions in membrane proteins that either affect protein folding, resulting in the degradation of the protein with a reduction in the level of mature protein (37-39); or affect glycosylation, processing, and transport, resulting in a decrease in the functional protein at the cell surface (35, 38, 40 -42) . The most striking example of such a phenomenon is the ⌬F508 mutant of the cystic fibrosis transmembrane conductance regulator. The mutant protein is misfolded, contains only core carbohydrates, and is rapidly degraded within a pre-Golgi compartment, resulting in a decrease in the level of mature protein in the cell (37) (38) (39) . In another example, a point mutation in the extracellular domain of the LH and FSH receptors resulted in core-glycosylated receptors that are retained in the endoplasmic reticulum of transfected cells (35) . The mutant LH receptor was unresponsive to its ligand because of its localization but bound its ligand in a permeabilized membrane binding assay. The analogous mutation in the closely related FSH receptor resulted in both retention in the endoplasmic reticulum and loss of ability to bind ligand, even in permeabilized cells (35) . In several other diseases, single-point mutations in GPCRs have been shown to abolish the ligand-binding ability of the receptor (40, 43, 44 ). In the type-2 vasopressin receptor, a point mutation in the first extracellular loop decreases the cell surface expression of the receptor as well as the affinity of the receptor for its ligand (40) , whereas the mutation of a conserved proline residue in the N-terminus of the PTH receptor affects the binding and, consequently, the signaling ability of the receptor, without affecting the cell surface localization of the receptor (44) .
To investigate the expression, glycosylation, and cellular localization of the GHRH receptor protein, and to determine whether differences in these processes might explain the loss of function of the little mutant receptor, we generated a receptor-specific polyclonal serum and used it to detect GHRH receptor protein in stably transfected HEK293 cells. Western blots of cells stably transfected with the wild-type and mutant GHRH receptor constructs indicate that both proteins are expressed and are of a comparable size and that the little mutation, which is only 10 residues away from the site of N-linked glycosylation of the receptor, does not inhibit core glycosylation of the receptor protein (Fig. 1) . This core glycosylation is comparable in both the wild-type and mutant receptors and is therefore unlikely to be a consequence of the mutation. Complex glycosylation could only be seen by cross-linking (Fig. 2) , which only shows receptors functional in binding and so could give no information about the little mutant.
Using the alternative detection strategy of epitope-tagging the receptor proteins, we observed that using equivalent amounts of wild-type and little DNA in transient transfection experiments resulted in equivalent levels of expressed receptors, suggesting that the little mutant protein does not have a significantly reduced stability. Interestingly, both Western protein blot analysis of the native receptors and immunoprecipitation of the epitope-tagged receptors indicate that the human GHRH receptor migrates more slowly than the mouse GHRH receptor, although the cDNAs from both species encode an identical number of amino acids and the proteins are predicted to have similar masses. This difference persists, even after complete deglycosylation with PNGase F, suggesting that the difference in mobilities between the two receptors is attributable to a higher negative charge in the human receptor (six more negative charges are expected, based on differences in protein sequence).
We were able to use the epitope-tagged GHRH receptors for immunofluorescence experiments designed to investigate cellular localization of the receptor proteins. Our studies, using both intact and permeabilized cells expressing the wild-type and mutant forms of the epitope-tagged mouse GHRH receptor, indicate that both receptors have a similar cellular distribution. Both receptors could be visualized on the cell surface in intact cells using confocal microscopy. Importantly, the mutant GHRH receptor does not seem to be trapped intracellularly to any extent. Overall, these results indicate that the wild-type and mutant GHRH receptor proteins have similar expression levels, glycosylation pattern, and cellular distribution, implying that the defect is at the level of binding or signaling.
To determine whether the little mouse GHRH receptor is defective in ligand binding, we found it necessary to develop a species homologous assay using iodinated mouse GHRH. Binding of human GHRH to the human, ovine, bovine, porcine, rat, and mouse receptors has been previously examined, and the mouse receptor was found to be the only one that did not bind human GHRH at appreciable levels. GHRH binding to mouse pituitary membranes displayed the same speciesspecificity as was seen with the recombinant mouse receptor (data not shown). This is most likely because, of all the characterized mammalian GHRH peptides, mouse GHRH has the least sequence similarity to human GHRH, with 11 substitutions or deletions in the biologically active region of the peptide, which includes residues 1-29 (45) (46) (47) . The decreased ability of the mouse GHRH receptor to bind human GHRH, combined with the relatively high nonspecific binding of GHRH to HEK293 cells, makes specific binding of iodinated human GHRH to the mouse receptor difficult to detect and explains previous difficulties in studying GHRH binding by the mouse receptor using the human peptide (48).
We observed a low level of GHRH-displaceable binding (Fig. 7) and GHRH-induced stimulation of cAMP (Fig. 8) in nontransfected HEK293 cells, even though GHRH receptor mRNA was not detectable in Northern blots of these cells. This trace binding to nontransfected cells could be significantly displaced by 50 m GTP␥S (Fig. 7) or 10 nm VIP (data not shown). The GTP␥S effect suggests that the observed binding is to a GPCR that can be uncoupled by the nonhydrolyzable GTP analog. As in our assay, 10 nm VIP does not displace GHRH binding to GHRH receptors (not shown); this suggests that the trace GHRH binding is caused by the ability of GHRH to cross-react with some closely related endogenously expressed GPCR, such as that for VIP or PACAP (49, 50) . Consistent with this idea, RT-PCR analysis, using degenerate primers designed to detect related receptors of this family, demonstrate that HEK293 cells express the type I PACAP receptor but not the GHRH receptor (unpublished results).
Our data indicate that the GHRH receptor bearing the little mutation is defective at the level of GHRH binding. When the homologous conserved aspartic acid residue was mutated in the related receptors for glucagon (51) and VIP (17) , the mutant receptors did not bind their respective ligands. This aspartic acid is conserved in nearly all known members of GPCR family B. Because these receptors bind diverse nonhomologous ligands (14) it is unlikely that it plays a role in the determination of ligand specificity. It is not anticipated that this aspartate interacts directly with GHRH; instead, this residue probably provides an acidic charge crucial for the structure or conformation required for hormone binding in all receptors of this family. Studies on the GHRH receptor have indicated that the N-terminus is essential for ligand binding (24 -26) and deletion of this domain or alterations, such as the introduction of an epitope-tag into this domain, can result in inactivation of the receptor (24) . Our current study demonstrates that the conserved aspartic acid at position 60 in the N-terminus of the GHRH receptor is essential for the interaction with the ligand, further supporting the role of the N-terminal domain in ligand recognition.
The discovery that the little mutation in mice is in the gene encoding the GHRH receptor (8, 9) provides support for the importance of the GHRH signaling system in normal growth. Our findings provide a cellular and molecular basis for understanding the defect in GHRH signal transduction in the little mouse and provide a foundation for further studies on the interaction of GHRH with its receptor.
